- >
- Blog
- >
- Capabilities
- >
- Page 3
The continued growth of virtual pharma – and the subsequent rise of virtual biotech – have made a lasting impression on the pharmaceutical contract manufacturing industry. Big Pharma firms, some…
‘One hundred percent purity’ is the holy grail of pharma – and, more generally, the scientific community. Firms in our industry all around the globe spend the overwhelming majority of…
7 ways to boost profits and reduce pharma synthesis waste At Neuland, we’re advocates of green chemistry. Not only is it better for the environment, but it’s also just logistically…
Since pioneers such as Bodanszky and Du Vigneaud first produced them synthetically in the 1950’s, peptides have always held tremendous – but unrealized – promise for human health. Despite their…
Reducing Mutagens, Carcinogens & Other Genotoxins to Improve Safety Profiles There are a number of process modifications API manufacturers can make to improve safety profiles, reduce production costs, improve capacity…
Active Pharmaceutical Ingredients (APIs, or – in layman’s terms – the ingredients that makes drugs work) have grown increasingly complex. Today’s equivalent of boiling tree bark into a tincture typically…
Last week, we wrote a post on new analytical methods for the detection of impurities that our R&D group had developed for the drug Febuxostat. And we’ve done the same…
In this month’s issue of PharmTech, team members at Neuland’s R&D Center in Hyderabad published a peer-reviewed article on the analysis and management of impurities in the drug Febuxostat. Febuxostat, a…
Hitting a milestone such as 30 years old as a pharmaceutical manufacturing company is a pretty big deal. Pharma – as you can imagine – has changed. A lot. Thirty…
